• Users Online: 586
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 4  |  Issue : 1  |  Page : 50-54

Non-small-cell lung cancer metastasis to unusual sites: A retrospective case series


1 Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
2 Department of Radiology, Tata Medical Center, Kolkata, West Bengal, India

Correspondence Address:
Sandip Ganguly
Department of Medical Oncology, Tata Medical Center, 14 Mar EW Arterial Road, Newtown, Kolkata - 700 160, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_359_20

Get Permissions

Background: The majority of all lung cancers are non-small-cell lung cancers (NSCLCs). They usually spread to the pleura, brain, adrenal gland, lungs, liver, and bones. However, clinical data for NSCLC metastasizing to unusual sites are sparse in the literature. Objectives: We aimed to assess the pattern of metastases to unusual sites and evaluate the clinicopathological characteristics, treatment details, and outcomes of patients with NSCLC. Materials and Methods: This retrospective case series was conducted in the Department of Medical Oncology of a tertiary cancer center in Eastern India between May 2011 and December 2018. Patients with cytologically or biopsy-proven treatment-naive stage IV NSCLC were included in this audit. Sites other than the pleura, brain, adrenal gland, lung, liver, and bones were considered as unusual sites of metastases. Clinicopathological characteristics, site of metastases, treatment details, and outcomes were recorded. Data were described using descriptive statistics, survival was estimated using the Kaplan–Meier analysis, and log-rank test was used to determine survival estimates. Results: A total of 1549 patients with metastatic NSCLC were registered, of which 121 (7.8%) had metastases to unusual sites. The median age of the cohort was 72 years (range, 19–87 years), and the male:female ratio was 7:1. The most common site of unusual metastasis was the skin with soft tissue, followed by the kidney; metastasis to these sites was seen in 31 (2%) and 26 (1.6%) patients, respectively. Systemic chemotherapy was given to 67 (55.3%) patients. At a median follow-up of 11.2 months (95% confidence interval [CI], 6.8–17.5), the median progression-free survival of the cohort was 5.9 months (95% CI, 3.8–9.1). Conclusions: In <10% of the patients, NSCLC can spread to unusual sites, most commonly to the skin/soft tissue and the kidney. A detailed discussion with the radiologists is necessary to distinguish NSCLC that has metastasized to unusual sites from second primary tumors and to avoid unnecessary tissue biopsies from these areas.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed182    
    Printed4    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal